Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-02-07 DOI:10.1016/j.tranon.2025.102318

Ting Lei , Yunjie Song , Zhiyi Shen , Yongqiang Shi , Cunyan Xia , Xu Deng , Wenyue Da , Yan Peng , Qing Li

{"title":"Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study","authors":"Ting Lei , Yunjie Song , Zhiyi Shen , Yongqiang Shi , Cunyan Xia , Xu Deng , Wenyue Da , Yan Peng , Qing Li","doi":"10.1016/j.tranon.2025.102318","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Malignant phyllodes tumors (MPTs) with sarcomatous components are often associated with substantial risks for local and distant recurrences. A more comprehensive characterization of their clinicopathological features and molecular profiles may offer significant potential innovative therapeutic strategies.</div></div><div><h3>Methods</h3><div>A total of ten cases were collected with eight cases undergoing DNA next-generation sequencing (NGS). The clinicopathological characteristics, prognostic information, and genomic profiles were compared to those of MPTs without sarcomatous components.</div></div><div><h3>Results</h3><div>Compared to MPT without sarcomatous components, no significant differences were found in age, tumor position, tumor size, menopausal status, or presence of fibroadenoma (<em>p</em> > 0.05). MPTs with osteosarcoma components had a poor prognosis either compared with other sarcomatous components (<em>p</em> = 0.027) or MPTs without sarcomatous components (<em>p</em> = 0.033). A notably high frequency of mutations was observed in several key genes within MPTs exhibiting sarcomatous components: <em>TP53</em> (<em>n</em> = 6, 75.0 %), <em>MUC16</em> (<em>n</em> = 4, 50.0 %), <em>PTCH1</em> (<em>n</em> = 3, 37.5 %), and <em>APC</em> (<em>n</em> = 3, 37.5 %). In MPTs characterized by sarcomatous components, <em>MCL1</em> (<em>n</em> = 6, 75.0 %) and <em>MYC</em> (<em>n</em> = 5, 62.5 %) demonstrated a notably high frequency of amplification. The NOTCH signaling pathway was significantly associated with MPTs characterized by sarcomatous components (13.6 % vs 75.0 %, <em>p</em> = 0.001).</div></div><div><h3>Conclusions</h3><div>The presence of an osteosarcoma component may serve as an indicator for unfavorable prognosis. Activating mutations in <em>TP53</em> have been identified in these tumors. Furthermore, it typically facilitates tumor formation and progression via the NOTCH signaling pathway. These findings may offer valuable insights for clinical prognosis and identify potential therapeutic targets.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"53 ","pages":"Article 102318"},"PeriodicalIF":5.0000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S193652332500049X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Malignant phyllodes tumors (MPTs) with sarcomatous components are often associated with substantial risks for local and distant recurrences. A more comprehensive characterization of their clinicopathological features and molecular profiles may offer significant potential innovative therapeutic strategies.

Methods

A total of ten cases were collected with eight cases undergoing DNA next-generation sequencing (NGS). The clinicopathological characteristics, prognostic information, and genomic profiles were compared to those of MPTs without sarcomatous components.

Results

Compared to MPT without sarcomatous components, no significant differences were found in age, tumor position, tumor size, menopausal status, or presence of fibroadenoma (p > 0.05). MPTs with osteosarcoma components had a poor prognosis either compared with other sarcomatous components (p = 0.027) or MPTs without sarcomatous components (p = 0.033). A notably high frequency of mutations was observed in several key genes within MPTs exhibiting sarcomatous components: TP53 (n = 6, 75.0 %), MUC16 (n = 4, 50.0 %), PTCH1 (n = 3, 37.5 %), and APC (n = 3, 37.5 %). In MPTs characterized by sarcomatous components, MCL1 (n = 6, 75.0 %) and MYC (n = 5, 62.5 %) demonstrated a notably high frequency of amplification. The NOTCH signaling pathway was significantly associated with MPTs characterized by sarcomatous components (13.6 % vs 75.0 %, p = 0.001).

Conclusions

The presence of an osteosarcoma component may serve as an indicator for unfavorable prognosis. Activating mutations in TP53 have been identified in these tumors. Furthermore, it typically facilitates tumor formation and progression via the NOTCH signaling pathway. These findings may offer valuable insights for clinical prognosis and identify potential therapeutic targets.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.